Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer

Abstract

This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13048-021-00785-1.

Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum‐resistant ovarian cancer

“…The probable reason would be that as discussed above, apatinib plus chemotherapy achieved a favorable treatment response compared to chemotherapy in patients with recurrent PROC, therefore expanding the survival profile. 23,[25][26][27] Moreover, peritoneum metastatic (yes vs. no) was independently related to poor DFS, while peritoneum metastatic (yes vs. no) and higher treatment lines were independently linked with shorter OS in patients with recurrent PROC, which were in accordance with the previous studies. 28,29 Furthermore, this study discovered that the incidence of hypertension was increased in patients with recurrent PROC receiving apatinib plus chemotherapy compared with patients receiving chemotherapy, which was in accordance with a previous study.…”

“…18 The possible reasons would be that: (1) apatinib itself could suppress angiogenesis, invasion, and migration 9 ; (2) apatinib plus liposomal doxorubicin or paclitaxel had a synergistic effect, which could enhance the anti-tumor effect of liposomal doxorubicin or paclitaxel, thus achieving a better treatment response in patients with recurrent PROC. 23,24 As a result, treatment response was improved in apatinib plus chemotherapy group compared with chemotherapy group. Apatinib plus chemotherapy prolongs the survival compared with chemotherapy in patients with recurrent PROC according to a previous study.…”